Placenta News and Research

RSS

WHO urged to establish a schedule to phase out the use of dental mercury fillings as soon as possible

Today, at an expert meeting on the future use of dental fillings, a letter signed by over 70 non-governmental organisations from around the world was presented, calling on the World Health Organization (WHO) to establish a schedule to phase out the use of dental mercury fillings as soon as possible.

17 Nov 2009

Two units of UCB reduce risk of leukemia from returning, shows new study

A new study from the Masonic Cancer Center, University of Minnesota shows that patients who have acute leukemia and are transplanted with two units of umbilical cord blood (UCB) have significantly reduced risk of the disease returning.

16 Nov 2009

New minimally invasive laser treatment saves the lives of twins with TTTS

As the number of women having twins has increased, so has the odds of developing a serious pregnancy complication called twin-to-twin transfusion syndrome (TTTS). This disorder affects as many as 15 percent of identical twin pregnancies, and results in uneven blood flow between the fetuses. Until recently the outcome was usually death or disabilities for the surviving babies.

13 Nov 2009

Exposure to deadly bacteria can result in stillbirths

A new study shows the risk for severe effects of exposure to Listeria monocytogenes among susceptible populations may occur at doses lower than suggested by previous studies.

13 Nov 2009

Nanoparticles may cause DNA damage across a cellular barrier

Scientists have shown in the laboratory that metal nanoparticles damaged the DNA in cells on the other side of a cellular barrier. The nanoparticles did not cause the damage by passing through the barrier, but generated signalling molecules within the barrier cells that were then transmitted to cause damage in cells the other side of the barrier.

5 Nov 2009

Compugen signs research and license agreement with a leading diagnostic company

Compugen Ltd. announced today that it has signed a research and license agreement with a leading diagnostic company covering CGEN-226, a novel biomarker candidate for early detection of preeclampsia.

5 Nov 2009

Risk of serious flu-related sickness far outpaces risk of injectable vaccine in pregnant women

Pregnant women who catch the flu are at serious risk for flu-related complications, including death, and that risk far outweighs the risk of possible side effects from injectable vaccines containing killed virus, according to an extensive review of published research and data from previous flu seasons.

30 Oct 2009

Absence of male hormones extends transplanted cell survival, says new study

Trophoblast stem cells (TSCs), cells found in the layer of peripheral embryonic stem cells from which the placenta is formed, are thought to exhibit "immune privilege" that aids cell survivability and is potentially beneficial for cell and gene therapies. Further, the survivability of TSCs has been thought to require the presence of ovarian hormones. However, none of these assumptions has ever been verified.

30 Oct 2009

Risk of serious flu-related sickness far outpaces risk of injectable vaccine in pregnant women

30 Oct 2009

Free, public lecture on hyperactivity

Biologist Theodore Garland will give an hour-long lecture, titled "Born to Run: Evolution of Hyperactivity in Mice," at 7 p.m., Thursday, Oct. 29, in the University Theatre on the UC Riverside campus. Doors open at 6 p.m. Seating is open.

24 Oct 2009

Study links urogenital birth defects with DDT

Women who lived in villages sprayed with DDT to reduce malaria gave birth to 33 per cent more baby boys with urogenital birth defects (UGBD) between 2004 and 2006 than women in unsprayed villages, according to research published online by the UK-based urology journal BJUI.

24 Oct 2009

DDT exposure is associated with urogenital birth defects in newborn boys

23 Oct 2009

Exposing pregnant women to chemotherapy does not affect the foetus

Professor Frederic Amant of the Katholieke Universiteit Leuven (K.U.Leuven) directs research into the treatment of cancer in pregnant women and the consequences of such treatment on foetal development. In her PhD dissertation on chemotherapy during pregnancy, Kristel Van Calsteren presents new scientific discoveries.

23 Oct 2009

Celgene announces fiscal 2009 third-quarter results

Celgene Corporation announced non-GAAP (Generally Accepted Accounting Principles) net income of $259.8 million, or non-GAAP earnings per diluted share of $0.56 for the quarter ended September 30, 2009. Non-GAAP net income for the third quarter of 2008 was $185.9 million, or non-GAAP earnings per diluted share of $0.40.

22 Oct 2009

UT student receives fellowship grant for pre-eclampsia research

Roxanna Irani, a M.D./Ph.D. student at The University of Texas Graduate School of Biomedical Sciences at Houston (GSBS), has received a $10,000 fellowship for her efforts to better understand a condition known as pre-eclampsia that threatens the lives of expectant women and their unborn children.

20 Oct 2009

Overview of innovative technology for treating ischemic and autoimmune disorders

Pluristem Therapeutics Inc. today announced that it will present at the New England-Israel Life Sciences Summit at the Brandeis International Business School in Waltham, Mass. Zami Aberman, chairman and CEO of Pluristem will present an update on the company and an overview of its technology at 9:40 EDT, Oct 27, 2009.

15 Oct 2009

NIH to launch 2009 H1N1 influenza vaccine trials in HIV-infected pregnant women, children and youth

The first clinical trials to test whether the 2009 H1N1 influenza vaccine can safely elicit a protective immune response in pregnant women launched yesterday, and a trial to conduct the same test in HIV-infected children and youth will begin next week.

12 Oct 2009

Liquorice consumption linked to shorter pregnancies and adverse affect on child's intelligence and behaviour

Expectant mothers who eat excessive quantities of liquorice during pregnancy could adversely affect their child's intelligence and behaviour, a study has shown.

7 Oct 2009

Pluristem commences dosing in Phase I clinical trial for the treatment of critical limb ischemia

Pluristem Therapeutics Inc. (NasdaqCM: PSTI; DAX: PJT) today announced the dosing of the first patient in the U.S. with its placenta-derived stem cell product, PLX-PAD, the Company’s leading candidate, in a Phase I clinical trial for the treatment of critical limb ischemia (CLI), the end-stage of peripheral artery disease (PAD).

23 Sep 2009

SHP-2 protein molecule encourages placenta growth

Scientists funded by the Biotechnology and Biological Sciences Research Council (BBSRC) have shown that a common biological protein molecule called SHP-2 is crucial for encouraging placenta growth. The research is published today in Endocrinology.

21 Sep 2009